Evogene
TASE:EVGN
₪
2,55
₪
+
₪0,03 (1,19%)
2,55
₪
+₪0,03 (1,19%)
End-of-day quote: 04/10/2026
Evogene Stock Value
Configure Widget
X
Create Widget
Not an affiliate? https://growth-software.de/partnerprogramm/
Widget copied to clipboard.
Evogene Company Info
EPS Growth 5Y
0,00%
Market Cap
₪0,03 B
Long-Term Debt
₪0,00 B
Quarterly earnings
05/20/2026 (E)
Dividend
₪0,00
Dividend Yield
0,00%
Founded
1999
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
There are currently no price targets available for this stock.
In the last five quarters, Evogene’s Price Target has risen from ₪0,00 to ₪2,55 - a 100,00% increase.
Top growth stocks in the health care sector (5Y.)
What does Evogene do?
Evogene Ltd. (Evogene) operates as a computational biology company.
The company focuses on life-science product discovery and development across several market segments, including human health, agriculture, and other industrial applications, by utilizing cutting-edge computational technologies.
The company established its unique CPB platform, leveraging big data and artificial intelligence, and incorporating deep multidisciplinary understanding in life sciences. The CPB platform is the basis f...
Evogene Ltd. (Evogene) operates as a computational biology company.
The company focuses on life-science product discovery and development across several market segments, including human health, agriculture, and other industrial applications, by utilizing cutting-edge computational technologies.
The company established its unique CPB platform, leveraging big data and artificial intelligence, and incorporating deep multidisciplinary understanding in life sciences. The CPB platform is the basis for three technology engines, each focused on the direction and acceleration of the discovery and development of products based on one of the following core components: Microbes – MicroBoost AI, Small molecules – ChemPass AI, Genetic elements – GeneRator AI. In 2024, the company emphasized its research and development efforts on MicroBoost AI and ChemPass AI. During 2025, it intends to direct its efforts by focusing further on the use of its ChemPass AI tech-engine in the field of AI-powered drug discovery in the pharma market segment. The company intends to continue the support and development of the MicroBoost AI and GeneRator AI tech-engines based on the needs of its subsidiaries, with their funding.
The company uses its technological engines to support the development of life science-based products through dedicated subsidiaries and with strategic partners. The company’s main activities are directed through its subsidiaries, which utilize the technological engines to develop human microbiome-based therapeutics by Biomica, ag-chemicals by AgPlenus, ag-biologicals by Lavie Bio, and castor seeds for bio-based industrial applications by Casterra.
In April 2024, the company and The Kitchen FoodTech Hub, or TKH, the foodtech incubator and investment arm of Israeli food giant Strauss Group, jointly announced the establishment of Finally Foods Ltd., or Finally. Finally is an AI-driven company specializing in molecular farming for the food sector, committed to providing sustainable alternative sources to animal-based proteins, while utilizing its GeneRator AI technology.
Business Model
The company capitalizes on the value of its AI tech-engines through two distinct business models:
Licensing: The company grants time-limited licenses to third parties, its subsidiaries, or related entities, allowing them to leverage its tech-engines for product development within specified commercial domains.
Collaborations: The company engages in collaborative ventures with industry leaders, pooling resources to drive joint product development. Typically, the company’s partners take the lead in later-stage development and commercialization, leveraging the company’s unique tech-engines to identify the product candidate and optimize it towards a commercial product.
As of December 31, 2024, Evogene commercialized MicroBoost AI through two licensing agreements, the first with its subsidiary, Lavie Bio, for the development of ag-biologicals, and the second with its subsidiary, Biomica, for the development of drugs based on the human microbiome. In addition, Evogene commercializes MicroBoost AI through collaboration with Verb Biotics LLC, to develop probiotic products.
With respect to ChemPass AI, Evogene commercializes it through a license agreement with the company’s subsidiary, AgPlenus, for the development of ag-chemical products.
With respect to GeneRator AI, during 2024, Evogene commercialized it through the following license agreements: the first with its subsidiary, Canonic, for the development of medical cannabis products. Canonic ceased its operation during the first half of 2024. The second, with its subsidiary, Casterra, for the development of castor seed varieties. The third, with Finally, to modify plants as ‘bioreactors’ to produce alternative sources to animal-based proteins. In addition, Evogene commercializes GeneRator AI through collaboration with Watershed AC, to establish crustacean gene editing technology.
Those license agreements and collaborations demonstrate how the company utilizes its business development and how it captures the value of its tech-engines to bring innovative products to market and revolutionize the life-science industry.
Major Occurrences and Developments
Evogene
ATM (March 2024) – Evogene entered into a Sales Agreement with Lake Street Capital Markets, LLC.
Established a new subsidiary (April 2024) – Evogene and TKH established Finally, specializing in protein production in plants for the food industry.
Collaboration (October 2024) - Evogene announced collaboration with Google Cloud to develop a foundation model for generative small molecule de novo design, propelling Evogene’s ChemPass AI tech-engine to new levels of innovation.
Registered Direct Offering and Private Placement (August 2024) - On August 23, 2024, Evogene entered into a definitive securities purchase agreement, or the Securities Purchase Agreement, with an institutional investor, or the Investor, pursuant to which it agreed to issue and sell to such investors in a registered direct offering, or the 2024 Offering.
Lavie Bio
Collaboration Agreement (February 2024) - Lavie Bio entered into an agreement for the discovery and development of new biological insecticidal solutions with Syngenta Crop Protection.
Sustainability (March 13) - Ceres Global Ag Corp. has chosen to include Lavie Bio’s Yalos bio-inoculant in regenerative agriculture initiatives in North America.
Joint Validation Trials (March 2024) – Lavie Bio extended its joint validation trials for its biofungicides conducted by Bayer AG, after successful first-year laboratory and greenhouse testing.
Pipeline (July 2024) - Lavie Bio announced the commercial expansion of Yalos to winter wheat and will commence sales across the United States for the 2024-2025 season.
Collaboration Agreement (July 2024) - Lavie Bio announced a significant milestone in its collaboration with ICL Group Ltd. to develop bio-stimulant solutions for key row crops facing extreme weather conditions by leveraging AI to identify over a dozen novel microbes within 12 months.
Grant (September 2024) – Lavie Bio received a grant from the IIA to advance its program to develop a technology for the delivery of ag-biologicals to agriculture. This patented technology, named ‘MicroFermentor’, is based on an innovative microbe formulation that enables the multiplication of beneficial bacteria directly on the plant, reducing application costs, extending shelf life, and prolonging the bacteria's viability after field application.
Pipeline (November 2024) - Lavie Bio announced the commercial expansion of Yalos as seed treatment for soybean, following successful field trials in 2024 in the US.
Pipeline (November 2024) - Lavie Bio announced advancement of its bio-fungicide LAV321, targeting Downy Mildew, to pre-commercial stage following successful 2024 field trial results in Europe.
Licensing (November 2024) - Lavie Bio announced the cancellation of its licensing agreement with Corteva. Lavie Bio regained full rights and freedom to operate the licensed technology and the lead bio-fungicide candidates.
Biomica
Clinical Trials - (January 2024) - Biomica enrolled the final patient in its Phase I clinical trial for microbiome-based immuno-oncology drug.
Positive Clinical Data Update (May 2024) – Biomica presented positive initial clinical data update from ongoing Phase 1 trial of microbiome-based therapeutic, BMC128, in patients with non-small cell lung cancer, or NSCLC, melanoma, or renal cell carcinoma, or RCC.
Casterra
Production Agreements (March 2024) – Casterra entered into agreements with seed producers in Brazil and Africa to meet growing demand for its castor seed varieties.
Production Agreements (May 2024) – Casterra entered into additional agreements with seed producers for the production of approximately 500 tons of seeds, to meet existing and growing demand for its castor seeds.
Production (July 2024) - Casterra announced the completion of a successful castor seed growing and harvesting season in Brazil, which will be ready for shipment during the third quarter of 2024, and in addition, Castor harvest season in Africa started as planned.
Production (October 2024) - Casterra announced a key milestone in its operational expansion plan in Africa, with completion of the first shipment of castor seeds grown and processed in Kenya. The shipment, comprising over 100 tons, was delivered to the company's customer in Africa.
AgPlenus
Licensing and collaboration agreement (February 2024) – AgPlenus entered into a licensing and collaboration agreement with Bayer AG for the development of a new sustainable weed control solution.
Collaboration Agreement (March 2024) – AgPlenus achieved a milestone in the collaboration with Corteva Agriscience (NYSE: CTVA) for the development of novel herbicides.
Market Segments
Agriculture
Lavie Bio Ltd.
In 2015, the company initiated its activity for developing ag-biological products as a division within Evogene, and early in 2019, it was organized under Lavie Bio Ltd., an independent company that, upon establishment, was wholly owned by Evogene.
Lavie Bio is focused on developing two main types of products: bio-pesticides, which are ag-biologicals for crop protection, addressing biotic stresses such as insects, diseases, and weeds, and bio-stimulants, which are ag-biologicals for crop enhancement, directly impacting crop yield or abiotic stress tolerance.
In August 2019, Corteva invested in Lavie Bio in a transaction that included the exchange of all shares of Corteva’s wholly-owned subsidiary, Taxon Biosciences.
In August 2022, ICL and Lavie Bio entered a multi-year collaboration agreement for developing novel bio-stimulant products to enrich fertilizer efficiency.
Business Model
Lavie Bio has defined two main models for market access:
Direct sales model – In fragmented markets, Lavie Bio expects to complete product development of its products independently, while establishing a tailored market access strategy per specific product and territory, such as commercialization through distribution channels. Under this model, the production of Lavie Bio’s products is achieved through third-party toll manufacturers. Revenues may include sales to distributors. Under the direct sales model, Lavie Bio has sold its inoculant Yalos in the U.S. for spring wheat growers.
Collaboration model – Lavie Bio offers tailored solutions to potential partners. In this model, Lavie Bio’s partner produces and commercializes the products being developed. Lavie Bio’s revenues in such engagements may include research and development payments, payments upon achievement of development milestones, and royalties. The scope of collaboration may differ. The typical model is that Lavie Bio develops a product until it is ready for commercialization, and the partner is responsible for the production and commercialization of the product. This model was used in the agreement with Corteva that was signed in July 2023, where Corteva received a license to Lavie Bio’s bio-fungicide product targeting fruit rots in grapes and other high-value crops.
Product Development Pipeline
Lavie Bio’s first product to reach the market is LAV.211, an inoculant for yield improvement, developed under Lavie Bio’s Bio-stimulants program for spring wheat and marketed under the brand name Yalos (formerly known as Thrivus). Yalos was commercially launched for 2022 spring wheat planting within target regions in North Dakota and Minnesota. In 2024, Lavie Bio has expanded sales in the United States to additional crops, such as durum and barley, and also expanded sales in new regions, such as Montana and Canada. In addition, in 2024, Lavie Bio proved the product's efficacy on soybeans and winter wheat, and plans to expand sales for these crops in 2025. In March 2024, the company reported that Ceres Global Ag Corp., or Ceres, a global agricultural, energy, and industrial products merchandising and supply chain company, has chosen Lavie Bio as a supplier in its sustainability programs with grain producers. Ceres will integrate Lavie Bio's bio-inoculant, Yalos, into its regenerative agriculture initiatives across the USA and Canada.
With respect to its Bio-pesticides program against fruit rots, in October 2022, Lavie Bio announced the submission to the EPA of a registration package for LAV.311, a bio-fungicide targeting fruit rots and powdery mildews. In July 2023, Lavie Bio announced the signing of a licensing agreement with Corteva. In November 2024, Lavie Bio announced that Corteva decided to terminate the licensing agreement and Lavie Bio regained full rights and freedom to operate the licensed technology and the lead bio-fungicide candidates.
On November 8, 2023, Lavie Bio reported significant progress with its bio-fungicide LAV321. In 2023, Lavie Bio achieved positive results in a series of field trials conducted across Europe and the United States, focusing on assessing LAV321’s efficacy in safeguarding crops against downy mildew and late blight diseases. Trials conducted across Europe achieved an average efficacy rate of ~55-60% against downy mildew in grapes. At Cornell University in New York, LAV321 demonstrated remarkable field trial results with a 97% efficacy rate against leaf disease and 53% against bunch disease. On November 19, 2024, Lavie Bio reported the advancement of LAV321 to Pre-Commercial stage, following successful field trials in Europe against downy mildew, reaching an average efficacy rate of 70%, and exceeding an average efficacy rate of 60% protecting tomato against late blight. These findings establish LAV321 as a potentially potent solution against fungal diseases, focusing on oomycetes class diseases, including downy mildew, late blight, and other blight diseases, all known for their destructive impact on crop yields.
With respect to Lavie Bio’s bio-stimulant programs for foliar application in soybean and cotton, on July 17, 2024, Lavie Bio and ICL reported significant advancement in the development of yield-increasing bio-stimulants, identifying more than a dozen novel microbial candidates to have commercial viability as bio-stimulants for crops grown under extreme weather conditions, including drought, achieved within its first months of collaboration and leading to successful field trials in the U.S. during 2024.
Key Collaborations
Corteva (originally with DuPont-Pioneer)
In July 2017, Evogene entered a multiyear collaboration with DuPont-Pioneer (now Corteva) for the research and development of novel microbial bio-stimulant seed treatments for the improvement of corn productivity globally. Following the establishment of Lavie Bio, the collaboration agreement was assigned from Evogene to Lavie Bio. Under the agreement, Lavie Bio is entitled to milestone payments for advancement of candidate strains, and royalties from product sales.
In July 2023, Lavie Bio signed a licensing agreement with Corteva.
ICL Group
In August 2022, Lavie Bio entered a multiyear collaboration with ICL for the research, development, and commercialization of novel bio-stimulant products to enrich fertilizer efficiency. Under the collaboration, Lavie Bio carries out dedicated product development programs, and ICL obtains exclusive commercialization rights for resulting candidate microbial products.
Syngenta
In February 2024, Syngenta and Lavie Bio announced a partnership to discover and develop novel bio-insecticide products.
Seasonality
Lavie Bio’s sale cycles and R&D activities are dependent on crop seasonality, as they are highly dependent on crop growing and harvest periods. For example, the use of Lavie Bio’s inoculant for yield improvement, Yalos, for spring wheat in North America requires that it be applied to wheat seeds in the second quarter of each calendar year (year ended December 31, 2024), guiding the sales cycles accordingly.
Government Regulation of the company’s Operations and of Product Candidates
In the U.S., the EPA regulates the company’s bio-pesticide products, while its bio-stimulant and bio-inoculant products are regulated as fertilizers, auxiliary plant substances, soil amendments, and/or beneficial substances in each of the 50 states.
The company’s first bio-stimulant product, LAV.211, was registered and is sold in certain U.S. individual states, as it does not require submission to the EPA. The company has received the Canadian Food Inspection Agency approval with respect to this product in the second quarter of 2023.
The company’s first bio-pesticide product candidate, LAV.311, has been submitted to the EPA for registration in October 2022, and is now undergoing the review process, expected to take 18-24 months before approval. Lavie Bio has been notified by the EPA of general delays in the registration process, extending the PRIA (Pesticide Registration Improvement Extension Act) date until further notice. Lavie Bio expects to receive the EPA's approval for LAV311 during 2025.
AgPlenus Ltd.
In 2015, the company initiated its activity for developing ag-chemical products as a division within Evogene, and in 2018, it announced that it had been organized under AgPlenus Ltd., a separate company, wholly owned by Evogene upon establishment.
AgPlenus’ activities focus on the discovery and development of new modes of action, or MoA, crop protection products.
Business Model
AgPlenus’ business model is based on two commercialization avenues:
Licensing of product candidates – When product candidates advance towards what is referred to in the industry as a Lead, at the end of the discovery stage, or further along the development pipeline, these product candidates gain increased value and can be candidates for licensing to ag-chemical companies. A typical licensing agreement can include upfront payments, payments upon achievement of pre-defined development milestones, and royalties from product sales.
R&D collaborations – Early-stage collaborations provide a tailored product offering per partner and product type, in order to build long-term research and development relationships and to mitigate the risk associated with building an independent pipeline. A typical collaboration agreement may include upfront payments, R&D payments, payments upon achievement of pre-defined development milestones, and royalties from product sales, which would typically be lower than the royalties under licensing agreements. AgPlenus may use collaboration partners for certain aspects along the development pathway.
AgPlenus’ revenues are derived from research and development payments under early-stage collaborations with Corteva. In the longer term, the company expects that as AgPlenus’ product candidates advance through development in its partners’ pipelines, and to the extent that they are commercialized by AgPlenus’ collaboration partners, revenues are expected to include milestone payments and royalty payments; and as AgPlenus’ internal pipeline product candidates further advance, AgPlenus will license its product candidates.
Product Development Pipeline
In 2024, AgPlenus partnered APTH1 with Bayer and continued to develop fungicides for the fungus, Zymoseptoria, responsible for Septoria Blotch in wheat.
Key Collaborations
Corteva – Herbicides
In March 2020, AgPlenus entered into a multi-year collaboration with Corteva for the discovery and development of novel herbicides.
Bayer AG – Herbicides
In February 2024, AgPlenus entered into licensing and collaboration agreements with Bayer AG for the development of a new sustainable weed control solution.
Intellectual Property
AgPlenus has three granted patents in Israel, and 38 patent applications for these three product candidates across various jurisdictions.
Ag-Seeds Division
The company’s seed traits activity is focused on the development of products improving seed traits that have a direct impact on crop productivity through the use of genetically modified, or GM, and non-GM approaches, aiming to fulfill such growing demand. The company mainly targets key commercial crops, such as corn, soy, wheat, rice, cotton, and canola.
The activities of this division are divided into four categories: yield & abiotic stress tolerance – to increase crop performance and productivity by enhancing yield, nutrient use efficiency, and tolerance to abiotic stresses, such as drought, heat, and salinity; disease resistance – to increase crop resistance to diseases, such as fungi and nematodes; insect control – to increase crop tolerance to pests; and food security - to create alternative sources to animal-based proteins.
In general, the company utilizes several biotechnology approaches with the goal of improving seed traits, including: genome editing technologies, enabling deletion or modification of specific genomic regions in the crop’s genome without inserting foreign DNA into the plant, genetic modification of plants, which involves the direct manipulation of a plant’s genome by inserting a gene into the plant’s DNA, and advanced breeding methods (e.g., genetic markers), whereby plants with favorable characteristics are selectively crossed through genomic-guided breeding schemes.
Business Model
In the Ag-Seeds division activity, the company collaborates with companies in the development of improved seed traits. The company’s partners include recognized seed companies, such as regional seed company Tropical Melhoramento & Genética S/A, or TMG, and Finally Foods Ltd. Typically, under these collaborations, the company performs the discovery phase, during which it discovers and validates candidate trait-improving genetic elements. Subsequently, the company’s collaborators, under license from the company, test and further develop these discoveries in their product development pipelines, starting Phase I, with the goal of introducing them into commercial crop seeds.
Key Collaborations
TMG
In December 2018, the company entered into a multi-year collaboration and license agreement with TMG, a major Brazilian developer and marketer of soybean varieties, for the development of nematode-resistant soybean varieties using genome editing technologies.
Crop4Clima
In May 2023, the company announced that it was awarded a grant as part of the Crop4Clima consortium funded by the EU Horizon’s EIC Transition program.
Finally Foods
In April 2024, the company and TKH jointly announced the establishment of Finally. Finally specializes in molecular farming for the food sector, committed to providing sustainable alternative sources to animal-based proteins while utilizing its GeneRator AI technology.
Government Regulation
The company’s operations are carried out mainly in Israel and accordingly are regulated by the ISARD, and more specifically by the ISARD’s Plants Protection and Inspection Services. The company is also obligated to obtain separate permits to own and operate its greenhouses and testing fields in Israel, and it is routinely inspected by ISARD.
Human Health
Biomica Ltd.
In 2017, the company established Biomica, a subsidiary focused on the discovery and development of innovative human microbiome-based therapeutics.
Biomica focuses on the development of human-microbiome based therapies utilizing either rationally-designed microbial consortia or small molecule approaches for (i) immuno-oncology, (ii) gastrointestinal inflammatory, or GI, related disorders, and (iii) antimicrobial resistance, or AMR, an antibiotic-resistant bacteria.
In December 2024, Biomica initiated two new discovery-stage programs:
Anti-Obesity – Designed to harness the microbiome to support weight loss and effective management of obesity.
Longevity – Focused on leveraging the microbiome to promote healthy aging by targeting age-related processes throughout the lifespan.
Product Development Pipeline
Immune-Oncology
BMC128 is a rationally designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by MicroBoost AI tech engine. Developed as a Live Bacterial Product, or LBP, BMC128 is an LBP consortium consisting of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbor specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes.
On January 17, 2024, Biomica announced that the final patient has been enrolled in its Phase I clinical trial.
On May 23, 2024, Biomica announced initial findings from an ongoing Phase 1 clinical trial. In the study, Biomica is investigating the safety and tolerability of its microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, an anti-PD1 immune checkpoint inhibitor, in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma (RCC).
Preliminary data from Biomica’s Phase 1 study of BMC128, in combination with ICI immunotherapy, in refractory patients, who previously progressed on immunotherapy, was presented at the American Society of Clinical Oncology Annual Meeting on June 3, 2024.
GI Disorders
In the IBD program, BMC333 is an optimized consortium, which consists of four bacterial strains derived from Biomica’s BMC321 and BMC322 (rationally-designed consortia that were identified using Biomica’s computational analysis and predictive capabilities designed with specific emphasis on the anti-inflammatory activity of these strains and their potential as novel therapeutic modalities for IBD). During 2024, Biomica continued scale-up development of BMC333. During 2025, Biomica plans to continue with the scale-up development in preparation for GMP clinical batch production of BMC333 pending sufficient funding.
In the IBS program, Biomica utilizes proprietary data from several clinical trials conducted in the U.S. to develop novel microbiome-based drug candidates, BMC426/7. On May 18, 2024, Biomica presented its results from pre-clinical studies in its IBS program at the Digestive Disease Week 2024 Annual Meeting. The pre-clinical work was performed in collaboration with the lab of Prof. Kara Gross Margolis, at the NYU Grossman School of Medicine. In the studies, Biomica tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427. Treatment with these drug candidates effectively reduced visceral pain, a major symptom of IBS.
AMR (antimicrobial resistance)
CDI – Using Biomica's microbiome therapeutics platform, the company is developing a small-molecule drug candidate (BMC201), designed to target the main toxin secreted by the bacterium and hence repair dysbiosis in the colonic microbiome in the setting of primary or recurrent CDI. BMC201 is being developed as an orally available drug.
MRSA – Biomica is engaged in a collaboration with the Weizmann Institute of Science in Israel to develop a selective treatment against antibiotic resistant strains of Staphylococcus aureus infection, in a microbiome-focused approach. Biomica has in-licensed Prof. Ada Yonath’s, Nobel Prize laureate, work and discoveries in high-resolution crystal structure of the large ribosomal subunit of the pathogenic Staphylococcus aureus for the design and development of new types of selective, narrow spectrum antibiotic agents.
Government Regulation
Biomica’s product candidates are subject to regulation by the FDA as biologics.
Industrial Applications
Casterra Ag Ltd.
The company’s activities related to castor seeds were initiated in 2007 and in 2012 were organized under a wholly owned subsidiary, currently named Casterra Ag Ltd. Casterra focuses on the development of an integrated solution for castor cultivation, including advanced non-GMO high-yielding castor seed varieties, growth protocols, and compatible agricultural machinery. During 2024, Casterra’s sales of seeds increased significantly, while also increasing its production capabilities by signing agreements with seed producers in Kenya and Brazil.
Competition
Casterra’s competition in its target markets mainly includes a few companies that supply castor seeds to growers worldwide, such as Kaiima Seeds and Terasol.
Business Model
Casterra’s business model is to sell its proprietary castor seed varieties to castor growers, together with targeted agro-technical growth protocols. Casterra’s offering includes high-yielding varieties with plant structures suitable for mechanized harvest, best practices for large-scale castor growing, and advanced compatible mechanical harvesting and dehulling solutions. Casterra is exploring the extension of its business model to include castor grain production.
Key agreements
Casterra Agreements with ENI and its Affiliate
On November 14, 2022, the company’s subsidiary, Casterra, entered into an agreement with an affiliate of ENI, whereby Casterra will provide its unique castor varieties and its broad know-how in the cultivation of castor at a commercial scale for biofuel production.
Intellectual Property
As of December 31, 2024, Casterra had registered its commercial varieties in Brazil and Argentina. In addition, Casterra filed a patent application with respect to a dehulling machine it developed.
Government Regulation of the company’s R&D Operations
Casterra’s activities in Israel in the field of seeds are regulated by the Israeli Ministry of Environmental Protection.
Research and Development
The company’s research and development expenses decreased to approximately $16.6 million for the year ended December 31, 2024.
Trademark
The company refers to various trademarks, service marks, and trade names that it uses in its business. The ‘Evogene’ design logo, ‘Evogene’, and other trademarks or service marks of the company and its subsidiaries are the property of the company or of its subsidiaries, as applicable.
History
Evogene Ltd. was founded in 1999. The company was incorporated in 1999.
This stock is not included in this month's Starter.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.
Stock added to your portfolio . To add it to another portfolio, click here.
